FFTY Performance — Innovator IBD(R) 50 ETF
Data updated: 2026-03-27
FFTY returned +2.63% year to date and +21.16% over one year to Jan 2026. Annualised returns are +16.56% over 3 years and −2.55% over 5 years. The fund beat its US Mid-Cap Growth category average: $100 invested three years ago grew to $158, against $142 for the category, and to $121 over one year, against $105. Volatility over the past three years was 23.84% a year. In the 12 months to Jan 2026 the fund took in a net $3.0M, and assets reached $85.88M.
FFTY Growth of $100
What $100 invested in Innovator IBD(R) 50 ETF grew to, compounded from monthly returns reported on SEC Form N-PORT, against the US Mid-Cap Growth category average over the same months.
| Period | FFTY | Category average |
|---|---|---|
| 1 year (Feb 2025 – Jan 2026) | $121 | $105 |
| 3 years (Feb 2023 – Jan 2026) | $158 | $142 |
| 5 years (Feb 2021 – Jan 2026) | $88 | $125 |
| Since data start (Feb 2020 – Jan 2026) | $107 | $172 |
FFTY Trailing Returns
Total returns to Jan 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +2.63% |
| 1 year | +21.16% |
| 3 years (annualised) | +16.56% |
| 5 years (annualised) | −2.55% |
FFTY Annual Returns
Calendar-year total returns of Innovator IBD(R) 50 ETF, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jan) | +2.63% |
| 2025 | +23.52% |
| 2024 | +18.44% |
| 2023 | +12.31% |
| 2022 | −51.04% |
| 2021 | +11.96% |
| 2020 (Feb–Dec) | +15.69% |
FFTY Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +2.6% | — | — | — | — | — | — | — | — | — | — | — |
| 2025 | +4.6% | −3.8% | −6.2% | +0.3% | +10.5% | +8.5% | +5.4% | +1.9% | +7.2% | +8.7% | −12.0% | −1.2% |
| 2024 | +2.1% | +10.5% | +0.6% | −7.1% | +7.5% | +0.6% | −5.5% | −1.0% | +3.5% | −0.8% | +18.4% | −8.7% |
| 2023 | +6.5% | −0.3% | +2.0% | −1.9% | −0.1% | +10.2% | +3.8% | −10.0% | −6.3% | −6.9% | +12.4% | +4.8% |
| 2022 | −17.2% | −0.2% | +3.1% | −16.9% | −1.1% | −16.3% | +5.8% | −0.6% | −13.5% | +7.1% | −2.5% | −12.1% |
| 2021 | +5.2% | +5.8% | −4.0% | +6.3% | −3.5% | +3.0% | −2.5% | +8.2% | −3.1% | +6.3% | −6.0% | −2.9% |
| 2020 | — | −8.7% | −13.6% | +7.4% | +7.0% | +7.2% | +7.3% | +4.4% | −3.5% | −3.4% | +9.9% | +3.8% |
FFTY Risk
Risk measures from monthly returns over Feb 2023 – Jan 2026.
- 3-year volatility (annualised): 23.84%
- 3-year Sharpe ratio: 0.51 (vs 4.5% risk-free rate)
- Best month: +18.42% (Nov 2024)
- Worst month: −11.97% (Nov 2025)
FFTY Fund Flows
Monthly money in and out of Innovator IBD(R) 50 ETF, from SEC Form N-PORT.
- 12-month net flow: $3.0M
- 12-month gross sales (incl. reinvestments): $66.0M
- Sales ÷ redemptions: 1.05×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jan 2026 | $7.4M | $1.9M | $5.6M |
| Dec 2025 | $3.6M | $14.1M | −$10.5M |
| Nov 2025 | $6.0M | $14.0M | −$8.0M |
| Oct 2025 | $9.9M | $4.0M | $5.9M |
| Sep 2025 | $22.1M | $1.8M | $20.4M |
| Aug 2025 | $0 | $11.6M | −$11.6M |
| Jul 2025 | $0 | $1.7M | −$1.7M |
| Jun 2025 | $1.6M | $3.1M | −$1.5M |
| May 2025 | $8.8M | $0 | $8.8M |
| Apr 2025 | $0 | $2.4M | −$2.4M |
| Mar 2025 | $0 | $4.1M | −$4.1M |
| Feb 2025 | $6.6M | $4.3M | $2.3M |
FFTY Assets Under Management
Net assets of Innovator IBD(R) 50 ETF by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-01-31 | $85.88M |
| 2025-10-31 | $113.80M |
| 2025-07-31 | $83.84M |
| 2025-04-30 | $60.92M |
| 2025-01-31 | $73.33M |
| 2024-10-31 | $62.74M |
| 2024-07-31 | $72.21M |
| 2024-04-30 | $83.47M |
| 2024-01-31 | $87.08M |
| 2023-10-31 | $73.94M |
| 2023-07-31 | $116.77M |
| 2023-04-30 | $77.74M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.